Literature DB >> 2160132

Clearance of tissue plasminogen activator by mannose and galactose receptors in the liver.

B Smedsrød1, M Einarsson.   

Abstract

The mechanism of uptake of radio-iodinated tissue plasminogen activator (125I-t-PA) was studied in rats. When trace amounts of 125I-t-PA were injected alone, the clearance followed a biphasic pattern in which 65% and 35% were cleared with alpha- and beta-kinetics (t1/2 (alpha) = 0.6 min, and t1/2 (beta) = 6.4 min), respectively. Co-injection with excess unlabelled t-PA or mannan changed the uptake kinetics to the monophasic beta-elimination pattern. Mannosylated albumin and ovalbumin, both of which bind to the hepatic mannose receptor, reduced the proportion of t-PA cleared with t1/2 (alpha) to 48% and 21%, respectively. A corresponding increase in the beta-elimination of t-PA was observed. The t1/2 (alpha) and t1/2 (beta) were unchanged. Studies on the clearance of 125I-ovalbumin also showed a biphasic elimination with an initial rapid phase, t1/2 (alpha), accounting for only 39% of the clearance of ovalbumin, as compared to 65% in the case of t-PA. Macromolecules with affinity for the galactose-receptor only, such as asialofetuin, or galactosylated albumin, did not significantly affect the clearance kinetics at the concentrations used. Asialoorosomucoid, which also carries galactosyl residues in the terminal position, reduced somewhat (from 65% to 48%) the proportion cleared with alpha-kinetics. Very high concentrations of galactose and N-acetyl-galactosamine, which are also known to compete for binding to the galactose receptor, lowered the proportion of t-PA cleared in the late beta-phase (reduced from 35% to 26% with galactose and to 19% with N-acetyl-galactosamine).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2160132

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  26 in total

Review 1.  Thyrotropin isoforms: implications for thyrotropin analysis and clinical practice.

Authors:  Joshua M Estrada; Danielle Soldin; Timothy M Buckey; Kenneth D Burman; Offie P Soldin
Journal:  Thyroid       Date:  2013-12-13       Impact factor: 6.568

2.  The physiological scavenger receptor function of hepatic sinusoidal endothelial and Kupffer cells is independent of scavenger receptor class A type I and II.

Authors:  Berit Hansen; Beatriz Arteta; Bård Smedsrød
Journal:  Mol Cell Biochem       Date:  2002-11       Impact factor: 3.396

3.  Advanced glycation end products are eliminated by scavenger-receptor-mediated endocytosis in hepatic sinusoidal Kupffer and endothelial cells.

Authors:  B Smedsrød; J Melkko; N Araki; H Sano; S Horiuchi
Journal:  Biochem J       Date:  1997-03-01       Impact factor: 3.857

Review 4.  Pharmacokinetics of recombinant bifunctional fusion proteins.

Authors:  Xiaoying Chen; Jennica L Zaro; Wei-Chiang Shen
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-03-20       Impact factor: 4.481

5.  Receptor-mediated endocytosis of ovalbumin by two carbohydrate-specific receptors in rat liver cells. The intracellular transport of ovalbumin to lysosomes is faster in liver endothelial cells than in parenchymal cells.

Authors:  G M Kindberg; S Magnusson; T Berg; B Smedsrød
Journal:  Biochem J       Date:  1990-08-15       Impact factor: 3.857

6.  Scavenger endothelial cells of vertebrates: a nonperipheral leukocyte system for high-capacity elimination of waste macromolecules.

Authors:  Tore Seternes; Karen Sørensen; Bård Smedsrød
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

7.  Distribution of plasminogen activator inhibitor in normal liver, cirrhotic liver, and liver with metastases.

Authors:  P Fitch; B Bennett; N A Booth; A Croll; S W Ewen
Journal:  J Clin Pathol       Date:  1994-03       Impact factor: 3.411

8.  Circulating C-terminal propeptide of type I procollagen is cleared mainly via the mannose receptor in liver endothelial cells.

Authors:  B Smedsrød; J Melkko; L Risteli; J Risteli
Journal:  Biochem J       Date:  1990-10-15       Impact factor: 3.857

9.  Pharmacokinetic and thrombolytic properties of unglycosylated recombinant tissue-type plasminogen activator (BM 06.021) produced in Escherichia coli.

Authors:  U Martin; S Fischer; U Kohnert; U Opitz; R Rudolph; G Sponer; A Stern; K Strein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-07       Impact factor: 3.000

Review 10.  Carbohydrate analysis throughout the development of a protein therapeutic.

Authors:  Elizabeth Higgins
Journal:  Glycoconj J       Date:  2009-11-04       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.